

NCT02733159 Raw comparison:

Summary:
CHIA has 22 criteria while your personal folder has 26 criteria
Total found criteria: 21/22
Total not Found: 1/22
Total Extra: 4
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Histologically confirmed PD-L1 status defined      │ Histologically confirmed PD-L1 status defined      │
│ NSCLC Biopsy must be within 70 days of first       │ NSCLC Biopsy must be within 70 days of first       │
│ treatment with pembrolizumab                       │ treatment with pembrolizumab                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ ECOG performance status 2                          │ ECOG performance status 2                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Life expectancy > 12 weeks                         │ Life expectancy \> 12 weeks                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Uni-dimensionally measurable disease according to  │ Uni-dimensionally measurable disease according to  │
│ Response Evaluation Criteria in Solid Tumours      │ Response Evaluation Criteria in Solid Tumours      │
│ (RECIST) v1 1                                      │ (RECIST) v1 1                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Computerised Tomography (CT) scan of chest and     │ Computerised Tomography (CT) scan of chest and     │
│ abdomen within 28 days of starting pembrolizumab   │ abdomen within 28 days of starting pembrolizumab   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Adequate haematological function                   │ Adequate haematological function                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Platelet count ≥100 x 109 /L                       │ Platelet count ≥100 x 109 /L                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Neutrophils ≥1 5 x 109/L                           │ Neutrophils ≥1 5 x 109/L                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Haemoglobin ≥ 9g/dL                                │ Haemoglobin ≥ 90 g/L                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Adequate hepatic function                          │ Adequate hepatic function                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum bilirubin ≤1 5 x upper limit of normal (ULN) │ Serum bilirubin ≤1 5 x upper limit of normal (ULN) │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum transaminases ≤2 5 x ULN                     │ Serum transaminases ≤2 5 x ULN                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Adequate renal function Creatinine clearance <1 5  │ Adequate renal function Creatinine clearance \<1 5 │
│ times ULN concurrent with creatinine clearance >50 │ times ULN concurrent with creatinine clearance     │
│ ml/min                                             │ \>50 ml/min                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Provision of signed and dated written informed     │ Provision of signed and dated written informed     │
│ consent prior to any study specific procedures     │ consent prior to any trial specific procedures     │
│ sampling and analyses                              │ sampling and analyses                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Untreated symptomatic brain or leptomeningeal      │ Untreated symptomatic brain or leptomeningeal      │
│ metastatic disease                                 │ metastatic disease                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Medical or psychiatric conditions comprising       │ Medical or psychiatric conditions compromising     │
│ informed consent                                   │ informed consent                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any medical condition which in the opinion of the  │ Any medical condition which in the opinion of the  │
│ investigator would compromise the ability of the   │ investigator would compromise the ability of the   │
│ patient to participate in the trial or which would │ patient to participate in the trial or which would │
│ jeopardise compliance with the protocol            │ jeopardise compliance with the protocol            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active autoimmune disease that has required        │ Active autoimmune disease that has required        │
│ systemic treatment in past 2 years                 │ systemic treatment in past 2 years                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Chronic usage of steroids or other                 │ Chronic usage of steroids or other                 │
│ immunosuppressant medication                       │ immunosuppressant medication                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previous history of pneumonitis                    │ Previous history of pneumonitis                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any evidence of clinical autoimmunity              │ Any evidence of clinical autoimmunity              │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal        │
╞════════════════════════════════════════════╡
│ Radiotherapy within 4 weeks of trial entry │
╘════════════════════════════════════════════╛



╒═══════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                       │
╞═══════════════════════════════════════════════════════════════════════════════════════════════╡
│ Core                                                                                          │
├───────────────────────────────────────────────────────────────────────────────────────────────┤
│ Radiotherapy within 28 days of trial treatment                                                │
├───────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                             │
├───────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patients who do not meet the criteria of performance status = 2 on the ECOG Performance scale │
╘═══════════════════════════════════════════════════════════════════════════════════════════════╛